Economic evaluation of an e-mental health intervention for patients with retinal exudative diseases who receive intraocular anti-VEGF injections (E-PsEYE) by Aa, H.P.A. (Hilde) van der et al.
 1van der Aa HPA, et al. BMJ Open 2017;7:e018149. doi:10.1136/bmjopen-2017-018149
Open Access 
AbstrAct
Introduction Because of the great potential of vascular 
endothelial growth factor inhibitors (anti-VEGF) for 
retinal exudative diseases, an increased number of 
patients receives this treatment. However, during this 
treatment, patients are subjected to frequent invasive 
intravitreal injections, and the effects on reversing the 
process of vision loss are uncertain, which may have 
negative consequences for patients’ mental health. One 
in three patients experience at least mild symptoms of 
depression/anxiety. To support patients in dealing with 
these symptoms, an e-mental health intervention (called 
E-PsEYE) has been developed. E-PsEYE is based on 
cognitive–behavioural therapy (CBT) and contains nine 
modules. A stepped-care model with three steps will be 
used to deliver the intervention: (1) providing information 
and psychoeducation, (2) when symptoms of depression/
anxiety persist, guided CBT is offered and supported by 
social workers from low vision rehabilitation services and 
(3) when symptoms still persist, patients are referred to 
their general practitioner.
Methods and analysis An economic evaluation from 
a healthcare and societal perspective will be conducted 
alongside a multicentre randomised controlled trial in 
two parallel groups to evaluate whether E-PsEYE is cost-
effective in comparison with usual care. Participants 
(n=174) will be 50 years or older, have retinal exudative 
diseases, receive anti-VEGF treatment and have mild 
symptoms of depression/anxiety (assessed prior to 
randomisation). Main outcome measures are: depression 
(Patient Health Questionnaire-9), anxiety (Hospital Anxiety 
and Depression Scale-Anxiety) and quality-adjusted life-
years (determined with the Health Utility Index-3 and the 
EuroQol-5 dimensions). Five measurements take place: at 
baseline and after 3, 6, 9 and 12 months.
Ethics and dissemination The study has been approved 
by the Medical Ethics Committee of the VU University 
Medical Centre Amsterdam. It will provide new and 
essential information on the cost-effectiveness of an 
innovative intervention for a vulnerable population. 
Outcomes will be disseminated through peer-reviewed 
publications and conference presentations.
trial registration http://www. trialregister. nl, identifier: 
NTR6337.
IntroductIon
Retinal exudative diseases (ie, age-related 
exudative macular degeneration, diabetic 
retinopathy and macula oedema) are the 
leading causes of vision loss in older adults.1 2 
They cause pathologically changed and newly 
formed blood vessels to leak and damage the 
retina, reducing vision. There is currently no 
cure for these diseases, but pharmacological 
inhibition of the vascular endothelial growth 
factor (anti-VEGF) in the eye can have a bene-
ficial effect. Anti-VEGF drugs that reduce the 
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Protocol
strengths and limitations of this study
 ► This is the first randomised controlled trial to 
investigate e-mental health in people with eye 
diseases/vision loss.
 ► The outcomes will provide new and essential 
information on the cost-effectiveness of an 
innovative intervention for a vulnerable population.
 ► The pragmatic design of the study provides a good 
representation of clinical practice that enables 
measuring all possible effects of the intervention 
and good external generalisability of the outcomes.
 ► Feasibility and implementability have a high priority 
in the study design, which is especially relevant in 
this vulnerable population.
 ► Participants and therapists cannot be masked due 
to the nature of the intervention, and some selection 
bias may be expected for which a non-response 
analysis will be performed.
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leakage and slow the growth of new blood vessels are 
injected into the eye at various intervals (often monthly). 
For approximately one-third of the patients, these injec-
tions lead to a substantial improvement in vision.3 There-
fore, anti-VEGF treatment is increasingly being offered 
in ophthalmic practice. However, about one-third has to 
deal with further vision loss despite treatment.1–3 
The uncertainty on reversing the process of vision loss 
and the frequently repeated invasive intravitreal injec-
tions that patients have to endure can have a great impact 
on patients’ mental health.4 Studies show that about one 
in three patients experience at least mild symptoms of 
depression and/or anxiety.4–6 These symptoms are the 
most important predictors of developing major depres-
sive or anxiety disorders7 and can lead to increased 
vision-specific disability,8 decreased health-related quality 
of life9 and increased mortality.10 Moreover, depression 
and anxiety generate substantial economic burden due to 
increased healthcare utilisation (ie, public mental health-
care use) and productivity losses.11–13
Research shows that e-mental health interventions are 
promising in reducing depression and anxiety in patients 
with chronic somatic disorders.14 15 Such interventions 
stimulate patient empowerment, are independent of time 
and place (which may lower barriers for receiving mental 
health services) and relatively little effort from profes-
sionals is needed, reducing healthcare costs.14 15
Therefore, E-PsEYE was developed for patients with 
retinal exudative diseases who receive anti-VEGF treat-
ment and experience mild symptoms of depression 
and/or anxiety. E-PsEYE is an e-mental health interven-
tion based on a guided self-help course with cognitive–
behavioural therapy (CBT), developed for patients with 
severe vision loss and at least mild symptoms of depres-
sion and/or anxiety from low vision rehabilitation organ-
isations and found effective as part of a stepped-care 
programme to prevent the onset of major depressive and 
anxiety disorders.16 This self-help course was modified for 
patients who receive anti-VEGF treatment and adjusted to 
an e-health intervention. Previous research showed that 
CBT can be effective in reducing depression and anxiety 
in people with visual impairment.16 17
Here we provide a protocol for an economic evaluation 
to investigate the cost-effectiveness of E-PsEYE in reducing 
depression and anxiety in older patients (aged ≥50 years) 
with retinal exudative diseases who receive intraocular 
anti-VEGF injections and to investigate the cost–utility for 
quality-adjusted life-years (QALYs) of E-PsEYE in compar-
ison with usual care.
MEthods
design
An economic evaluation from a healthcare and a societal 
perspective will be performed alongside a single-masked, 
multicentre (ie, five Dutch hospitals will participate), 
randomised controlled trial. Measurements will take 
place at baseline and after 3, 6, 9 and 12 months.
randomisation
Participants will be individually randomised according 
to a 1:1 ratio to usual care or E-PsEYE plus usual care. 
A computerised random number generator will be used 
to produce the allocation scheme. This will be based on 
random sequence block randomisation (blocks of 2, 4 
and 6) and stratified by the five participating hospitals. 
Randomisation takes place after the baseline measure-
ment by an independent researcher. Patients will receive 
the outcome of randomisation by email. Due to the nature 
of the intervention, participants and therapists cannot 
be masked. At the outset of the study and during each 
contact with the research team, participants are told not 
to divulge the nature of their treatment allocation. We 
will check if masking is maintained by asking the research 
assistant to guess which treatment arm was offered.
Intervention
E-PsEYE is based on CBT and contains nine web-based 
modules, which patients follow at home or at any other 
place they prefer during a period of up to 3 months. A 
stepped-care model with three steps will be used to deliver 
the intervention. (A) First, a welcome module, containing 
information about retinal exudative diseases, anti-VEGF 
treatment and psychoeducation will be offered. Previous 
studies have shown that mild symptoms of depression/
anxiety may decrease by only providing psychoeduca-
tion.18 19 If required, an Information and Communication 
Technology (ICT) trainer from Royal Dutch Visio (RDV; 
the low vision rehabilitation organisation that participates 
in this study) will provide a computer training explaining 
the software features of E-PsEYE before participants 
start using the intervention. (B) If mild symptoms of 
depression and/or anxiety persist, the eight CBT-based 
follow-up modules will be provided. These eight modules 
are aimed at: dealing with (1) uncertainty surrounding 
anti-VEGF treatment; (2) depression and anxiety; (3) 
fatigue and stress; (4) participating in pleasurable activ-
ities; (5) replacing self-defeating thoughts with healthier 
thoughts; (6) identifying and replacing negative thought 
patterns; (7) identifying and replacing negative commu-
nication styles; and (8) setting goals for the future. Guid-
ance during step two will be provided by trained and 
supervised social workers (n=4) from RDV. After partic-
ipants have finished exercises as part of each module, 
social workers will receive a notification by email. Within 
a week, the social worker provides feedback on the exer-
cises (digitally or by telephone, depending on patients’ 
preferences) with the aim to clarify information and moti-
vate patients to persist in carrying out the course. The 
intensity of guidance will depend on patients’ needs and 
will be accurately reported (max. 2 hours in total). (C) If 
mild symptoms of depression and/or anxiety still persist 
after E-PsEYE, patients are referred to their general prac-
titioner (GP) to discuss further treatment.
Social workers will be trained in delivering guidance 
(6 hours in total) by the researcher (background in social 
work) and the ICT expert from RDV. Training consists of 
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Figure 1 Overview of the study design and patient flow.
a workshop during which the study and intervention are 
explained, a course in providing the online intervention 
and the role as coach is provided (2 hours) and practice 
in two patient representatives while receiving intensive 
supervision (4 hours). Additionally, intervision sessions 
will be organised during the trial by social workers 
themselves.
usual care
Usual care in both the intervention and control group 
includes care provided at the ophthalmology depart-
ments of the five participating Dutch hospitals (including 
intraocular anti-VEGF treatment and other care aimed 
at improving patients’ vision or stabilising vision loss), 
which is reported by means of case report forms, and/or 
care provided by other healthcare providers (including 
low vision rehabilitation services), which is measured with 
the iMTA Medical Consumption Questionnaire (iMCQ; 
see www. imta. nl).
sample size
The sample size calculation was based on our former 
study on the effectiveness of a stepped-care intervention 
in older patients from low vision rehabilitation organisa-
tions,16 since E-PsEYE was based on the second step of 
this intervention. In the current study, we aim to reduce 
both depressive and anxiety symptoms. Therefore, our 
sample size calculation was based on the outcomes of 
the Centre for Epidemiologic Studies Depression Scale 
(CES-D), which covers both depressive and anxiety symp-
tomatology.20 21 Twelve months after the guided self-help 
course (on which E-PsEYE was based), we found a mean 
difference of 2.5 on the CES-D. In our current study design 
with four follow-up measurements (after 3, 6, 9 and 12 
months), sample sizes of 65 per arm achieve 80% power to 
detect a difference of 2.5, having a compound symmetry 
covariance structure when the SD is 6.4, the correlation 
between observations within the same subject is 0.5 and 
the alpha level is 0.05 (two sided). Taking into account, a 
drop-out rate of 25% after 12-month follow-up16; sample 
sizes of 87 per arm (total: n=174) are needed.
recruitment and study proceedings
A total of 1600 patients from the five participating Dutch 
hospitals (±320 patients per hospital) who receive intra-
ocular anti-VEGF injections will be addressed by letter 
to participate in the RCT in two waves (July 2017 and 
November 2017) to be able to include enough partic-
ipants. Since we expect that about one-third has mild 
symptoms of depression and/or anxiety, about 40% 
will be willing to participate, and 83% has access to the 
group.bmj.com on March 13, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
4 van der Aa HPA, et al. BMJ Open 2017;7:e018149. doi:10.1136/bmjopen-2017-018149
Open Access 
internet (based on unpublished pilot data), we expect to 
be able to include 174 eligible participants. If our expec-
tations are incorrect, we will be able to address more 
patients at the participating hospitals to take part in our 
study. Patients will receive a letter from their ophthalmol-
ogist, in which all necessary information regarding the 
study, as well as an invitation to participate is included. 
When patients consider participating, they will receive 
additional information from the research team. Based on 
this information, written informed consent is obtained. 
Baseline measurements (ie, digital questionnaires, with 
guidance by telephone if needed) will be performed to 
determine eligibility. Subsequently, eligible patients are 
either enrolled in the E-PsEYE intervention in addition 
to receiving usual care or will receive usual care only (see 
figure 1 for an overview of the study design and patient 
flow).
Digital questionnaires will be used to collect the data. 
Guidance by telephone will be provided by the research 
team if needed. Data will be entered into Castor (data 
entry software) and converted into the statistical software 
package SPSS for Windows V.22 and R Studio, V.0.99.896. 
For each participant, a code (from 1000 to 5999) is used. 
A ‘key file’ (in which these codes are linked the patients’ 
names, addresses and phone numbers) will be saved 
separately and will be deleted after the study has ended. 
Data will be stored at the VU University Medical Centre 
computer network with password. Written questionnaires 
and signed consent forms will be kept in a locked cabinet 
in a locked room, only accessible to the research team. 
Data will be stored for 15 years before being destroyed.
Participating in this study is with negligible risk. There-
fore, appointing a data monitoring committee is not 
needed. However, it is possible that the intervention will 
cause adverse events (ie, undesirable experiences occur-
ring to a participant during the study). All adverse events 
will be recorded by the research team. All serious adverse 
events (ie, any untoward medical occurrence or effect 
that results in death, is life threatening, requires hospital-
isation, results in significant disability or incapacity or any 
other important medical event) will be reported by the 
research team to the accredited medical ethics committee 
within 7 days. All events will be followed until they have 
abated, or until a stable situation has been reached and 
the patient’s GP is contacted.
Participants
In order to be eligible to participate in this study, patients 
must meet all of the following criteria: (1) they should 
be 50 years or older; (2) they should be diagnosed with 
a retinal exudative disease (ie, macular degeneration, 
diabetic retinopathy and/or macula oedema caused by 
retinal vein occlusion); (3) they should be treated with 
anti-VEGF injections; (4) they should have at least mild 
symptoms of depression and/or anxiety (a score of 5 or 
higher on the Patient Health Questionnaire (PHQ)-922 
and/or a score of 3 or higher on the Hospital Anxiety and 
Depression Scale-Anxiety (HADS-A))23; (5) they should 
be able to speak the Dutch language adequately; and (6) 
they should have access to the internet.
Patients are excluded from participation in this study 
if: (1) they are cognitively impaired, which is assessed by 
telephone with a score <3 on the six-item Mini Mental 
State Examination24; (2) have a score of 20 or higher on 
the PHQ-9, indicating severe symptoms of depression 
because the E-PsEYE intervention would then not be 
suitable; (3) indicate to be suicidal (ie, patients respond 
positively on the PHQ-9 suicide item); and (4) are heavy 
drinkers (score of 8 or higher on the Alcohol Use Disor-
ders Identification Test.25 These patients will be referred 
to their GP to discuss other (more intensive) treatment 
options. Subjects who have a score of 20 or higher on the 
PHQ-9 or who indicate to be suicidal during the follow-up 
measurements will also be contacted by telephone by the 
research team to discuss if a direct referral to their GP is 
necessary.
outcome measures
Demographics and anti-VEGF treatment
Demographics and comorbid conditions will be measured 
at baseline, and life events in the past year (eg, getting 
injured or developing a serious illness, getting divorced, 
the death of a relative or close friend) will be measured 
after 12 months (self-rated). Information on anti-VEGF 
treatment (eg, frequency, period, monocular vs binoc-
ular) and visual acuity will be collected at baseline, and 
after 3 and 12 months from patient files at the partici-
pating hospitals.
Primary clinical outcomes
Symptoms of depression and anxiety are measured with 
the PHQ-9 and HADS-A22 23 at baseline, and after 3, 6, 
9 and 12 months. The PHQ contains nine questions on 
a 4-point Likert scale, ranging from 0 (not at all) to 3 
(nearly every day). Total scores range from 0 to 27, with 
a cut-off score of ≥5 indicating mild depression. The 
PHQ-9 is widely used and is considered a valid and reli-
able tool to measure depression in older adults with 
vision loss.22 The HADS-A has seven items on a 4-point 
Likert scale, with a total score ranging from 0 to 21 and a 
cut-off score of ≥3 for mild anxiety. The reliability of the 
HADS-A is reported to be ‘good to very good’ in older 
adults.23 Health-related quality of life is measured at base-
line, after 3, 6, 9 and 12 months with the Health Utility 
Index Mark 3 (HUI-3)26 and the EuroQol-5 Dimensions 
with five levels (EQ-5D-5L),26 27 which are used to deter-
mine QALYs. The EQ-5D-5L is the preferred measure to 
determine QALYs in economic evaluations.27 We added 
the HUI-3 since it specifically covers sensory impairment, 
which is relevant in our study population.26
Secondary clinical outcomes
Adaptation to vision loss is measured with the 9-item 
Adaptation to Vision Loss (AVL) scale,16 28 illness cogni-
tions (related to helplessness, acceptation and disease 
benefits) are measured with the 18-item Illness Cognition 
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Table 1 Overview of all measurements and instruments
Baseline 3 months 6 months 9 months 12 months
Cognitive functioning: six-item MMSE24 x
Alcohol use: AUDIT25 x
Demographics and comorbidities x
Life events in the past year x
Anti-VEGF treatment x x x
Depressive symptoms: PHQ-922 x x x x x
Anxiety symptoms: HADS-A23 x x x x x
Health-related quality of life: HUI-3 and EQ-5D26 x x x x x
Adaptation to vision loss: AVL28 x x x
Illness cognitions: ICQ29 x x x
Vision-related quality of life: LVQOL30 x x x
Mastery: PMS31 x x x
Cognitive therapy skills: CCTS-SR32 x x x
Healthcare utilisation: iMCQ x x x x x
Absence/presenteeism work: iPCQ33 x x x x x
Process evaluation x
AUDIT, Alcohol Use Disorders Identification Test; AVL, Adaptation to Vision Loss; CCTS-SR, Competencies of Cognitive 
Therapy Scale-Self Report; EQ-5D, EuroQol-5 Dimensions; HADS-A, Hospital Anxiety Depression Scale-Anxiety; HUI-
3, Health Utility Index Mark 3; ICQ, Illness Cognition Questionnaire; iMCQ, iMTA Medical Consumption Questionnaire; 
iPCQ, iMTA Productivity Cost Questionnaire; LVQOL, Low Vision Quality of Life; MMSE, Mini Mental State Examination; PHQ, 
Patient Health Questionnaire; PMS, Pearlin Mastery Scale; VEGF, vascular endothelial growth factor.
Questionnaire,29 vision-related quality of life is measured 
with the 18-item Low Vision Quality of Life question-
naire,16 30 mastery is measured with the 7-item Pearlin 
Mastery Scale31 and cognitive therapy skills are measured 
with the Competencies of Cognitive Therapy Scale-Self 
Report of which two versions will be used: a 29-item patient 
version and a 9-item therapist version.32 These secondary 
clinical outcomes are measured at baseline and after 3 
and 12 months.
Cost-evaluation outcomes
The iMCQ is used to measure healthcare utilisation (eg, 
the number of contacts with a GP, physiotherapist, social 
worker, psychologist, hours of homecare received and 
medication use) and the iMTA Productivity Cost Ques-
tionnaire is used to measure and value absence and 
presenteeism from paid and unpaid work (eg, number 
of sick days and number of days less productive; see www. 
imta. nl)33 at baseline, after 3, 6, 9 and 12 months. Stan-
dard costs for healthcare utilisation from the recently 
updated Dutch costing manuals will be used (see guide-
line at www. zorginstituut. nl). In addition, the costs of the 
intervention will be measured, which depends on the 
number of people who only follow the first module and 
those following the total intervention. Medication use 
is valued using prices from Dutch Medical costs guide-
lines (www. medicijnkosten. nl). Productivity losses will 
be valued using the friction cost approach, assuming 
that after a certain period of time (ie, 161 days), the sick 
employee is replaced.34 Therefore, lost productivity costs 
are generated only during the friction period.
Process evaluation outcomes
Compliance is operationalised in the intervention group 
after 3 months by patients rating their effort and social 
workers rating patients’ compliance to the E-PsEYE inter-
vention, based on a 10-point scale (0=no effort/compli-
ance to 10=full effort/compliance). In addition, patients 
are asked to keep a diary on how often and for how long 
they used the intervention. Recall is operationalised 
after each module in step 2 by social workers rating the 
degree to which patients seem to remember last modules 
on a 10-point scale (0=patient remembers nothing to 
10=patient remembers everything). Patient satisfaction 
is measured with the Dutch Mental Healthcare ther-
mometer of satisfaction.35 This is a widely used 20-item 
questionnaire on patients’ satisfaction with provided 
information, their relationship with the social worker and 
results of the treatment. Therapist satisfaction and adher-
ence is measured by means of evaluation forms filled out 
by social workers during the intervention, containing 
information on: time spent on guided support by email 
or telephone, time after responding to exercises that 
were performed by participants, time spent on intervision 
sessions and satisfaction with the intervention. An over-
view of all measurements and instruments is provided in 
table 1.
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statistical analysis
Clinical effectiveness analysis
The study will be conducted in adherence to the Consol-
idated Standards of Reporting Trials (CONSORT) guide-
lines. Two-sided tests will be used with a significance 
level of p<0.05. Linear mixed modelling will be used to 
compare change in all primary and secondary clinical 
outcome measures over time between trial arms, which 
will be based on the intention-to-treat principle (ie, data 
of all randomised patients will be included independent 
of treatment completion). If necessary, the models will 
be adjusted for confounders. Questionnaires with latent 
constructs will be analysed using item response theory 
models.
Cost-effectiveness and cost–utility analysis
Both a cost-effectiveness analysis (CEA), with the PHQ-9 
and the HADS-A as primary measures of effectiveness, 
and a cost–utility analysis (CUA), based on QALYs, from 
a healthcare and societal perspective will be performed. 
Missing cost and effect data will be imputed using multiple 
imputation techniques according to the Multivariate 
Imputation by Chained Equations (MICE) algorithm.36 
The results of the imputed datasets will be pooled using 
Rubin’s rules.37 Bias-corrected and accelerated bootstrap-
ping with 5000 replications will be used to calculate 95% 
CIs around the mean difference in total costs between the 
two groups for both perspectives. Incremental cost-effec-
tiveness ratios (ICERs) will be calculated. Bootstrapping 
will be used to estimate the uncertainty surrounding the 
ICERs, which will be plotted graphically on cost-effec-
tiveness planes. Cost-effectiveness acceptability curves 
will also be estimated. Findings will be integrated with 
published reports and literature to extrapolate the find-
ings to a national level.
Budget impact analysis (BIA)
Based on the results of the clinical study, the CEA and 
the CUA, a BIA will be performed to inform decision 
makers on the financial consequences of implementing 
E-PsEYE in routine practice. Guidelines by the Interna-
tional Society for Pharmacoeconomics and Outcomes 
Research (ISPOR) Task Force will be used for the BIA, 
that is, relevant features of the healthcare system, access 
restrictions, anticipated uptake and the use and effect 
of current and new intervention(s) will be taken into 
account. The BIA will be performed from the perspec-
tive of: (1)society (including both direct healthcare and 
indirect non-healthcare costs) and (2) health service 
providers and health insurers (including only direct 
healthcare costs). The trial results will be extrapolated, by 
means of a simple model, from a time horizon of 2 years 
to 5 years, concerning the entire Dutch population. Due 
to a lack of registration, only an estimation of the number 
of people who receive anti-VEGF injections in the Neth-
erlands can be provided based on GP registrations. The 
extrapolation will assume a constant incidence of clini-
cally significant symptoms of depression and anxiety in 
older adults who receive anti-VEGF treatment. Also, we 
expect that the detection rate as found in the trial will 
be stable over time. Therefore, the extrapolation will be 
linear. A factor that is expected to change with time is the 
uptake of the E-PsEYE intervention. This factor will be 
used for scenario analysis in the BIA. For each perspec-
tive, we assess costs when 10%, 20%, 30% and 100% of 
the target group receive E-PsEYE. These scenarios will be 
compared with the baseline scenario, reflecting current 
care, where 0% of the target group is offered E-PsEYE. 
Sensitivity analyses will be performed on relevant param-
eters such as the uptake of E-PsEYE and unit costs. The 
source of the unit prices will vary with the perspective. 
Also, future costs will be indexed and not discounted. The 
precision of costs will be in accordance with the described 
perspectives. In addition, a modelling approach will be 
used to provide a wider range of estimates in which cost 
estimates from the trial results will be combined with data 
from the literature.
Implementation
During the E-PsEYE trial, a problem analysis study on 
barriers and facilitators for implementation will be 
conducted to identify and target barriers for nationwide 
implementation. This will be a qualitative study including 
semistructured interviews with patients, ophthalmol-
ogists, heads of ophthalmology departments, social 
workers and managers from low vision rehabilitation 
organisations. The number of participants will depend on 
the moment when saturation of data is reached, that is, 
when more data will not lead to more information. All 
interviews will be recorded by a digital voice recorder 
and transcribed verbatim using F4 software.38 Data will be 
analysed using Atlas.Ti software (V.7.5) and the so-called 
‘framework method’ will be used, which combines deduc-
tive and inductive forms of analysis and is most commonly 
used for the thematic analysis of semistructured interview 
transcripts.39 Based on the information obtained by these 
interviews, an implementation plan will be developed.
dIscussIon
Older patients with retinal exudative diseases who receive 
anti-VEGF treatment often experience mental health 
problems.4–6 These problems can lead to increased 
vision-specific disability,8 decreased health-related quality 
of life,9 increased mortality10 and generate substantial 
economic burden due to increased healthcare utilisation 
and productivity losses.11–13 Therefore, extensive research 
on mental healthcare for these patients is warranted.
Based on previous studies,14–16 we expect that the 
CBT-based e-mental health intervention E-PsEYE may 
provide a solution. E-PsEYE stimulates a collaboration 
between ophthalmologists, who primarily focus on 
curing the patient in the limited time that is available to 
them, and low vision rehabilitation professionals, who 
have the means and expertise to provide the necessary 
mental health support. Moreover, E-PsEYE is accessible 
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(ie, independent of time and place: patients can use it at 
home), it stimulates patient empowerment and relatively 
little effort from professionals is needed, which may result 
in a cost-effective intervention.
To the best of our knowledge, this is the first randomised 
controlled trial to investigate e-mental health in people 
with eye diseases or vision loss. By testing E-PsEYE to reduce 
symptoms of depression and anxiety in this vulnerable 
population, this study is highly relevant to patients, clini-
cians and society in general. Moreover, because a struc-
tured evaluation of the feasibility and implementability of 
E-PsEYE is explicitly taken into account in the design of 
this study, the results will greatly contribute to the prac-
tical evidence about treatment options for depression 
and anxiety in patients with retinal exudative diseases 
who receive anti-VEGF treatment. In addition, the study 
covers a variety of medical fields, that is, low vision reha-
bilitation, ophthalmology, gerontology, epidemiology 
and psychology, that could benefit from the results.
Another strength of this study is the pragmatic design 
that was chosen in which patients, treatments and proce-
dures are similar to daily clinical practice. This greatly 
enhances the generalisability of the results and possibil-
ities for implementation.
A limitation of this study is that participants and thera-
pists cannot be masked due to the nature of the interven-
tion, which could lead to information bias—for instance, 
participants who receive E-PsEYE may have more atten-
tion on treatment outcomes, which may lead to an over-
estimation of the results. However, because we chose a 
pragmatic design for our study, we expect to be able to 
give a good representation of actual clinical practice. 
Second, although we use a well-designed randomisation 
procedure with allocation concealment, some selection 
bias may be expected because patients who volunteer 
and will be selected for this study may differ from other 
eligible individuals. We will perform a non-response anal-
ysis to examine these differences. Third, E-PsEYE will only 
be accessible to people who use the internet. Still, this 
group of people is vastly increasing, even among older 
adults.40
EthIcs And dIssEMInAtIon
The study protocol was approved by the Medical 
Ethics Committee of the VU University Medical Centre 
Amsterdam, the Netherlands and will be conducted 
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published in peer-reviewed journals.
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